IMMUNOLOGIC PARAMETERS IN SYSTEMIC SCLEROSIS
- 1 January 1994
- journal article
- Published by Wiley in International Journal of Dermatology
- Vol. 33 (1) , 25-32
- https://doi.org/10.1111/j.1365-4362.1994.tb01488.x
Abstract
Immunologic abnormalities seem to play an important role in important role in systemic sclerosis (SSc). We studied the following immune parameters to get more insight into SSc: autoantibodies (antinuclear antibodies (ANA), anti-Scl-70, anticentromere antibodies (ACA) subsets of lymphocyte subpopulations and markers of their activation, as well as serum levels of IL-2, the soluble IL-2 receptor (SIL-2R), IL-6 and its correlation to N-terminal procollagen-III propeptide (P III P), and finally, the IL-6 production by SSc and normal dermal fibroblasts. In patients with active SSc, we found a reduced number of CD2+ T-lymphocytes and an increase in the expression of T-lymphocyte activation markers such as CD25+ and CD71+, HLA-DR Ia, as well as elevated serum levels of SIL-2LR and IL-6. SSc fibroblasts did not produce more IL-6 than normal fibroblasts in monolayer cultures. Our data show that a wide range of immunologic parameters are altered in SSc. In general, T-helper (TH) lymphocytes are activated possibly because of reduced T-suppressor (TS) and natural killer (NK)-cell levels. TH may polyclonally stimulate B cells, which in turn produce higher amounts of autoantibodies. Our findings support the concept that TH cell-derived cytokines/growth factors stimulate matrix protein synthesis by fibroblasts, resulting in generalized fibrosis.Keywords
This publication has 50 references indexed in Scilit:
- Enhanced expression of high-affinity interleukin-2 receptors in scleroderma: Possible role for IL-6Clinical Immunology and Immunopathology, 1992
- Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With SclerodermaArthritis & Rheumatism, 1992
- Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection.Annals of the Rheumatic Diseases, 1991
- Soluble immunologic products in scleroderma seraClinical Immunology and Immunopathology, 1991
- Biological and clinical aspects of interleukin 6Immunology Today, 1990
- Interleukin-6: historical background, genetics and biological significanceImmunology Letters, 1990
- The role of interleukin 2 in autoimmunityImmunology Today, 1989
- Systemic scleroderma: Clinical and pathophysiologic aspectsJournal of the American Academy of Dermatology, 1988
- Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosisArthritis & Rheumatism, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987